undamentalytics Newsletter
Sign in

Akebia Therapeutics, Inc. cash flow statement

In fiscal 2025, Akebia Therapeutics, Inc.'s operations generated $68.0m of cash; it spent $291,000 on capital projects, leaving free cash flow of $67.7m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−27−5258−56−97−257−110−253−73−23−416842
Depreciation and amortisation0001122222112
Stock-based pay65691912242318981113
Capital spending0032270000001
Free cash flow−28−5355−58−99−264−111−253−73−23−416840
Free cash flow after stock pay−34−5849−67−118−276−135−276−91−33−485627
Share buybacks0————————————
Shares issued104——373—————————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: AKBA vs PBYIAKBA vs IDYAAKBA vs ANABAKBA vs VALN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Akebia Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Akebia Therapeutics, Inc.